Ten FDA-approved adalimumab biosimilars are now available in the United States. If you or a family member takes Humira for rheumatoid arthritis, Crohn's disease, psoriasis, or any of Humira's other approved indications, you've probably been confronted with the biosimilar question in some form — from your insurance, your pharmacy, or your doctor.
The options can feel overwhelming. This guide explains what actually matters when comparing these drugs, and which ones have the strongest programs for patients struggling with cost.
What Is a Biosimilar?
A biosimilar is a biological medicine that is highly similar to an already-approved "reference" drug — in this case, Humira (adalimumab). Biosimilars go through an FDA approval process that requires demonstrating they are clinically equivalent to the reference drug in terms of safety, purity, and potency.
Biosimilars are not generics. Generic drugs are chemically identical copies of small-molecule drugs. Biological drugs like Humira are large, complex molecules produced by living cells, which means no two batches are perfectly identical even within a brand-name drug. "Biosimilar" means clinically equivalent, not chemically identical.
What Does "Interchangeable" Mean?
Some biosimilars have earned an additional FDA designation: interchangeable. An interchangeable biosimilar has met a higher standard of evidence that it can be substituted for the reference drug — or switched back and forth — without loss of efficacy or increased safety risk.
Practically speaking, interchangeable designation means a pharmacist can substitute the biosimilar for Humira without a new prescription from your doctor (state pharmacy laws vary, but most allow this). It does not mean your doctor is required to switch you.
FDA-designated interchangeable adalimumab biosimilars as of 2026:
- Cyltezo (adalimumab-adbm) — Boehringer Ingelheim
- Yuflyma (adalimumab-aqvh) — Celltrion
- Hyrimoz (adalimumab-adhi) — Sandoz
- Hadlima (adalimumab-bwwd) — Organon/Samsung Bioepis
The Citrate-Free Distinction
The original Humira formulation contained citrate as a buffer, which caused a mild stinging sensation at the injection site. AbbVie later reformulated to a citrate-free version — and most newer biosimilars have also launched in citrate-free formulations.
If injection-site discomfort has been an issue, make sure your biosimilar prescription specifies a citrate-free formulation. Not all biosimilars offer both; check with your pharmacist.
Citrate-free adalimumab biosimilars: Yuflyma, Hyrimoz HD, Hadlima HD, Cyltezo
The 10 FDA-Approved Adalimumab Biosimilars
| Biosimilar | Manufacturer | Interchangeable | Citrate-Free Option | |---|---|---|---| | Amjevita | Amgen | No | No | | Cyltezo | Boehringer Ingelheim | Yes | Yes | | Hadlima | Organon/Samsung | Yes | Yes (HD) | | Hulio | Mylan/Viatris | No | No | | Hyrimoz | Sandoz | Yes | Yes (HD) | | Idacio | Fresenius Kabi | No | No | | Simlandi | Alvotech/Teva | No | Yes | | Yuflyma | Celltrion | Yes | Yes | | Adalimumab-bwwd | Samsung Bioepis | Yes | Yes | | Lyumjev (investigational) | Varies | Pending | Varies |
Patient Assistance Programs by Manufacturer
This is often the most important comparison for uninsured and underinsured patients.
Cyltezo (Boehringer Ingelheim) One of the stronger PAP offerings in the biosimilar space. Boehringer Ingelheim has a patient assistance foundation, and Cyltezo has a formal GoodRx partnership for uninsured patients. A $0 copay option is available for eligible commercially insured patients.
- Contact: cyltezo.com or 1-833-CYLTEZO
Hadlima (Organon) Offers a PAP plus a "Ready for Health" program that includes free nurse coaching to support the transition from Humira. Income thresholds are comparable to myAbbVie Assist.
- Contact: hadlima.com
Hyrimoz (Sandoz) Sandoz has a broad patient assistance program. Hyrimoz is one of the more widely available biosimilars in retail pharmacies and has been on most major formularies since its launch.
- Contact: sandozus.com/patients
Amjevita (Amgen) The Amgen Assist 360 program covers Amjevita. Amgen has an established infrastructure for patient assistance, and Amgevita was the first adalimumab biosimilar to launch in the U.S.
- Contact: amjevita.com or 1-888-762-6436
Yuflyma (Celltrion) Celltrion offers copay assistance for commercially insured patients and a separate patient assistance program for uninsured/underinsured. The citrate-free formulation makes it a common choice for patients with injection-site sensitivity.
- Contact: yuflyma.com
Which One Should You Ask For?
If your insurance has a preferred biosimilar, start there — using a non-preferred biosimilar when a preferred option exists almost always costs more.
If you're uninsured or paying out of pocket, Cyltezo's GoodRx partnership and Hadlima's nurse support program are worth prioritizing. Call each manufacturer's patient line to compare current eligibility before applying.
If you're a stable patient on Humira who's being asked to switch, see our article on what the clinical evidence says about switching — and under what circumstances you can push back.
ClariMeds can evaluate your eligibility across all biosimilar assistance programs at once.
Find out which program fits you — about 5 minutes
Program terms, eligibility, and formulary status change frequently. Verify current terms directly with the manufacturer or your insurer.